Nebokitug shows sustained benefits for moderate, advanced PSC
A year of treatment with Chemomab Therapeutics’s candidate nebokitug reduces key disease biomarkers and the occurrence of clinical events that reflect disease progression among…
Cholangitis
2nd-line PBC treatment options call for personalized care: Analysis
Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…
Trial testing golexanolone as PBC treatment delayed
A Phase 1b/2 trial testing Umecrine Cognition’s golexanolone in primary biliary cholangitis (PBC) patients with cognitive symptoms and fatigue has been delayed due to…
Canadian scientists given grant to advance ways of treating PSC
Conscience, a Canadian nonprofit, has awarded CA$461,241 (nearly $320,000) to a research project aiming to provide preclinical data that could lead to new approaches…
How I advocated for my brother before and after his PSC diagnosis
“I can’t explain why, but I don’t feel well,” my younger brother, Osari, said. He was 32 years old at the time. That statement was…
CM-101 (nebokitug) set for primary sclerosing cholangitis Phase 3 trial
Chemomab Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on the best path toward regulatory approval of its investigational therapy nebokitug,…
Seladelpar conditionally approved in European Union to help treat PBC
Gilead Sciences’ oral therapy seladelpar has been conditionally approved by the European Commission as a second-line therapy for adults with primary biliary…
2nd liver transplant linked to good outcomes in PSC
A second liver transplant results in transplant and patient outcomes in people with primary sclerosing cholangitis (PSC) that are comparable or better than those…
Antibiotic may ease IBD related to primary sclerosing cholangitis
Four weeks of treatment with vancomycin, a common antibiotic, lowered inflammatory bowel disease (IBD) in people with primary sclerosing cholangitis (PSC), data from a…
Poor primary biliary cholangitis outcomes tied to two antibodies
Testing positive for the self-reactive anti-gp210 and anti-centromeric antibodies significantly increases the risk of poor liver-related outcomes for people with primary biliary cholangitis (PBC),…
